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Current influenza virus vaccines are based on strain-specific surface glycoprotein hemagglutinin (HA) antigens and
effective only when the predicted vaccine strains and circulating viruses are well-matched. The current strategy of influenza vaccination does not prevent the pandemic outbreaks and protection efficacy is reduced or ineffective if
mutant strains emerge. It is of high priority to develop effective vaccines and vaccination strategies conferring a broad
range of cross protection. The extracellular domain of M2
(M2e) is highly conserved among human influenza A viruses and has been utilized to develop new vaccines inducing cross protection against different subtypes of influenza
A virus. However, immune mechanisms of cross protection
by M2e-based vaccines still remain to be fully elucidated.
Here, we review immune correlates and mechanisms conferring cross protection by M2e-based vaccines. Molecular
and cellular immune components that are known to be involved in M2 immune-mediated protection include antibodies, B cells, T cells, alveolar macrophages, Fc receptors,
complements, and natural killer cells. Better understanding
of protective mechanisms by immune responses induced by
M2e vaccination will help facilitate development of broadly cross protective vaccines against influenza A virus.
[Immune Network 2015;15(5):213-221]
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INTRODUCTION
Influenza viruses are enveloped, single-stranded, negative-sense RNA viruses and belong to the family Orthomyxoviridae. Influenza viruses are classified into main
types A, B, and C. These main antigenic types are differentiated not only on the basis of antigenic differences in
their nucleocapsid (NP) and matrix (M) proteins, but also
with respect to the number of gene segments and viral proteins, host range and capacity to cause disease (1). Influenza B viruses are restricted to human hosts. Influenza A viruses that have many different hosts including humans,
birds, and pigs are divided into subtypes based on hemagglutinin (HA) and neuraminidase (NA) proteins on the surface of the virus. At present, 18 different HA (H1-H18)
and 11 different NA (N1-N11) molecules are known to exist (2).
The gene 7 among 8 segmented genes of influenza A
virus is bicistronic, encodes both M1 and M2 proteins. The
M2 protein is derived from the co-linear (M1) transcript
by splicing. M2 is an integral membrane protein, whose
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membrane-spanning domain also serves as a signal for
transport to the cell surface. M2 protein is also known to
be a proton-selective ion channel to control the pH of the
Golgi during HA synthesis and responsible for the acidification of the viral interior during uncoating and membrane fusion (3,4). The 23-amino acid sequence in the extracellular domain of M2 (M2e) is well conserved among
human influenza A viruses although there are few residue
changes among non-human host species such as avian and
swine influenza A viruses (5-7). Especially, the MSLLTEVET sequence (aa 1-9) in M2e was found to be conserved at a rate of over 99% among all influenza A viruses
(5,8) because these residues are shared with those of M1.
Therefore, M2e-based vaccines may be developed into attractive candidates for a universal influenza vaccine with
a broad spectrum of prevention.
M2e itself is known as a very poor immunogen. Even
live influenza virus infection generating strong humoral
and cellular immunity is not effective in inducing M2especific antibodies in a mouse model (9,10). Therefore,
previous studies have focused on increasing the immunogenicity of M2e using a variety of carrier vehicles or in
combination with various adjuvants. Examples of carrier
vehicles for M2e antigens include hepatitis B virus core
particles (11-13), human papillomavirus L proteins (14),
phage Qβ-derived protein cores (15), keyhole limpet hemocyanin (16), bacterial outer membrane complexes (12,
17), liposomes (18), cholera toxin subunit (19), flagellin
(20), and virus-like particles (9). Adjuvant formulations
that were reported with M2e antigens include complete or
incomplete Freund’s adjuvant (12,16,21), monophosphoryl
lipid A (MPL) (18,19,22,23), cholera toxin subunits (24),
heat-labile endotoxin (8,11,13,25), cholera toxin, and liposome based cationic adjuvant (26). Also, recombinant live
vectors expressing M2e antigens that were tested in animal
models are to utilize adenovirus (16) or modified vaccinia
virus Ankara (27). Most studies described above reported
that M2e-based vaccines even with potent experimental adjuvants can provide survival protection but are not capable
of completely preventing weight loss after lethal challenge
with different strains of influenza A virus. Thus, studies
on the protective efficacies by M2e-based vaccination, involving a certain degree of body weight loss, suggest that
M2e immunity-mediated cross protection is relatively weak.
Despite extensive reports with M2e-based vaccines, the
mechanism studies of cross protection by the immune re214

sponses induced by M2e vaccination have been relatively
rare. Most licensed human vaccines are based on the induction of neutralizing antibodies. However, M2e immunity confers protection through non-neutralizing immune mechanisms. In this article, we have reviewed the
possible immune mechanisms of M2e-mediated protection.

M2e ANTIBODIES AND ANTIGENIC BINDING
PROPERTIES
The M2 protein is not only expressed at a low level on
the virions but also shielded by the larger and more abundant surface HA and NA glycoproteins (28). Immunization
with whole-inactivated or split influenza vaccine in mice
was not effective in inducing M2e-specific antibodies (10,
22,28-30), probably because shielding effects by HA and
NA proteins might prevent the access of M2e to immune
effector cells. In contrast, the M2 protein is expressed at
high levels on the plasma membrane surfaces of virus-infected cells (31,32). Mouse anti-M2e monoclonal antibody
14C2 has been reported to reduce plaque sizes of some
influenza A virus strains in vitro but not other strains
(A/PR/8/34, A/WSN/34) (32). Moreover, passive immunotherapy with 14C2 monoclonal antibody reduced human
influenza virus replication in the lung of mice (33).
M2e vaccines either in carrier vehicles or in adjuvant
formulations were shown to induce M2e-specific antibodies conferring survival advantages but not being able
to prevent weight loss upon lethal infection. M2e vaccine-induced M2e antibodies are highly effective in binding to M2e peptide antigens but show low or no reactivity
to M2 protein antigens on influenza virions (9,34,35). M2e
vaccine immune sera were shown to be reactive to M2
proteins expressed on the surfaces of infected cells (3435). In general, M2 immunity provides weak protective efficacy, which might be due to the fact that anti-M2e antibodies cannot neutralize the virus in vitro (33,35,36).

IMPROVED CROSS PROTECTION BY
HETEROLOGOUS M2e DOMAINS PRESENTED
ON VIRUS-LIKE PARTICLES
Although M2e sequences are highly conserved in human
influenza A viruses, there are minor variations in the M2e
sequences derived from avian and swine influenza A viruses (5). In a strategy to overcome these M2e sequence
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variations, a heterologous tandem repeat of M2e epitope
sequences (M2e5x) of human, swine, and avian origin influenza A viruses was expressed in a membrane-anchored
form and incorporated into virus-like particles (M2e5x
VLP) (9,10). The M2e epitope density of M2e5x construct
on VLPs as probed by M2e specific monoclonal antibody
was detected at hundreds fold higher than those in influenza virions and wild type M2 on VLPs (9,10). Recombinant
M2e5x VLP vaccine has several unique features using genetic engineering techniques, which are different from other M2e vaccines. (i) The M2e5x protein contains heterologous M2e sequences with a linear tandem array of conserved M2e sequences derived from human, swine, and
avian host origin influenza A viruses for broader coverages. (ii) The oligomerization domain of general control
nondepressible 4 (GCN4) to stabilize oligomer formation
was genetically fused to the C-terminal part of M2e5x. (iii)
The signal peptide from the honeybee protein melittin was
added to the N-terminus of M2e5x, which is known for
efficient expression on insect cell surfaces (37). (iv)
Finally, the transmembrane and cytoplasmic tail domains
were replaced with those derived from HA to take advant-

age of its high levels on influenza virus, expecting for efficient incorporation into VLPs.
Immunization of BALB/c mice with M2e5x VLP experimental vaccines effectively induced M2e antibodies that
were highly reactive to M2e antigens of human, swine, and
avian influenza viruses. Serum antibodies induced by
M2e5x VLP immunization were found to be highly reactive
with different influenza viruses including H1N1, H3N2 and
H5N1 subtypes (9,10). Compared to mono M2e or homologous tandem M2e vaccines, M2e5x VLP vaccine was demonstrated to be highly efficacious in conferring cross protection against H1N1, H3N2, and H5N1 subtype viruses
by 100% protection with preventing severe weight loss in
the absence of exogenous adjuvants (9,10). In addition, immune sera were found to be sufficient for conferring cross
protection against H1N1, H3N2, and H5N1 influenza virues
in naïve mice (9,10). It is significant to provide strong evidence that M2e-specific antibodies can have cross protective roles although these M2e antibodies lack in vitro
virus neutralizing activity. However, it is difficult to compare the efficacy of different M2e-based vaccines that were
reported by other laboratories under different conditions.

Table I. Humoral and cellular immune mechanisms for M2e immunity
mAb, Vaccines

Humoral mechanism

M2e mAb (14C2)
M2e mAb (14C2)
M2e-HBc
M2 DNA/Adenovirus
CTA1-M2e-DD
M2 VLP /inactivated virus
M2e5x VLP/AS04
M2e-HBc immune IgG

Plaque reduction
Passive protection
IgG1, IgG2a
IgG
IgG1, IgG2a
IgG, protection against body weight loss
IgG
Passive immunization and protection

M2e5x VLP
M2e5x VLP
M2e5x VLP

IgG, protection
IgG1, IgG2a, virus binding, protection
IgG1, IgG2a, virus binding, long-term
protection (8 months)
IgG1, IgG2a, protection against body
weight loss
mAb IP passive immunization and protection
Polyclonal IgG, IP passive protection

M2e5x VLP/split vaccine
M2e mAb (Z3G1)
M2e-HBc sera

Cellular mechanism

NK cells-mediated ADCC
CD4＋ and CD8＋ T cells (depletion)
B cell-independent, MHCII-CD4＋ T cells
Macrophages, dendritic cells
Granzyme B＋, IFN-γ＋CD4＋ T cells
FcγRI, FcγRIII-dependent alveolar
macrophages (Passive)
CD4＋, CD8＋ T cells, Fc receptors (active)
Fc receptors (passive)
IFN-γ＋ spleen cells
Fc receptors (passive), CD4＋, CD8＋
T cells (depletion)
C3-dependent reduction in viral loads
C3-independent protection

References
(32)
(33)
(35)
(16)
(19)
(29)
(22)
(47)
(48)
(10)
(9)
(30)
(56)
(35)

M2e mAb, M2e specific monoclonal antibody; M2e-HBc, M2e-hepatitis B virus core fusion protein; M2 VLP, virus-like particles (VLP)
presenting the wild type M2 protein; M2e5x VLP, VLP presenting a heterologous tandem repeat of M2e epitope sequences (M2e5x) of
human, swine, and avian origin influenza A viruses; NK cells, natural killer cells; ADCC, antibody-dependent cellular cytotoxicity;
CTA1-M2e-DD, M2e fusion protein vaccine to cholera toxin subunit A1 and a dimer of the D-fragment of Staphylococcus aureus protein
A; AS04, adjuvant of alum plus monophosphoryl lipid A (MPL), Protection against body weight loss indicates significantly improved
cross protection by preventing severe weight loss.
IMMUNE NETWORK Vol. 15, No. 5: 213-221, October, 2015
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MECHANISMS OF M2e-BASED VACCINES IN
CONFERRING CROSS PROTECTION AGAINST
INFLUENZA
Multiple mechanisms might be involved in conferring protection by M2e-specific antibodies. It was suggested that
M2e-specific antibodies could perturb crucial interactions
between the M1 and M2 proteins and subsequently interfere with the interaction of the M1 protein with the HA
protein, the NA protein, and the nucleocapsid complexes,
thus interfering with virus assembly and causing growth
restriction (7). Moreover, anti-M2e antibodies bind strongly to the virus-infected cells, proposing indirect mechanisms of protection. Non-neutralizing antibody-mediated
protective mechanisms are antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytolysis (CDC),
preventing the release of viral particles into the extracellular fluids, and/or enhancing the uptake by phagocytic
cells. Potential immune mechanisms by which M2e-based
vaccines or M2e antibodies confer protection are summarized in the Table 1.

Roles of Fc receptors in conferring cross protection by
M2e antibodies
Neutralization of virions is believed to be the primary
function of antibodies in anti-viral immunity (38-43). It is
also known that Fc receptor (FcR)-mediated phagocytosis
by macrophages plays a pivotal role in clearance of influenza A virus-infected cells (44,45). Previous studies have
shown that anti-M2e antibodies passively transferred could
mediate protection against influenza infection in vivo
(13,46). Given the fact that anti-M2e antibodies are nonneutralizing antibodies, FcR-mediated opsonophagocytosis
by macrophages could be essential for M2e-specific antibody-mediated immune protection. El Bakkouri et al. demonstrated that alveolar macrophages and FcR-dependent
elimination of influenza A virus-infected cells are crucial
for protection by anti-M2e IgG using passive immunization experiments in wild-type and FcR common γ chain
−/−
deficient (FcR γ ) mice models as well as a conditional
cell depletion and adoptive transfer protocol (47). Moreover, Song et al. also reported that cross protection against
influenza A virus by M2e-immune sera is mediated by
dendritic cells and macrophages as shown by depletion experiments using clodronate-liposomes (20).
To better understand M2e immune-mediated protection,
216

antibody levels and protective efficacy were compared be−/−
and wild type BALB/c mice that were
tween FcR γ
immunized with M2e5x VLP (48). M2e antibodies in FcR
−/−
mice were induced at similar levels and showed
γ
equal protective capacity as observed in wild type BALB/c
mice. However, M2e5x VLP-immunized FcR γ−/− mice
were much less protected than M2e5x VLP-immunized
−/−
wild type mice after lethal challenge. In contrast, FcR γ
mice that were immunized with inactivated influenza virus
effectively induced hemagglutination inhibition (virus neutralizing) activity and were well protected. These studies
indicate that HA-based vaccines inducing virus neutralizing antibodies confer strain-specific protection in an Fc receptor independent mechanism whereas M2e antibodymediated cross protection requires Fc receptors (48). In
line with this mechanism, immune sera with M2e anti−/−
bodies showed much less protective efficacies in FcR γ
mice compared to those in wild type mice using a modified passive immunization approach (10,30). Taken together, a possible explanation is that M2e-specific antibodies
are contributing to protection via FcR expressing host immune cell-dependent mechanisms because these antibodies
cannot directly neutralize influenza A virus. Alternatively,
anti-M2e antibodies may promote the adaptive response by
enhancing uptake of antibody-bound virions via dendritic
cells and macrophages which are not by themselves sufficient for protection. It is also possible that immune-complex activated dendritic cells and macrophages further contribute to increasing antiviral IFN-γ-secreting T cell responses.

Roles of natural killer cells in conferring cross
protection by M2 immune responses
The FcR γ subunit is known to be required for antibodymediated phagocytosis by macrophages and for natural
killer (NK) cell-dependent ADCC (35). In mice, contradictory findings have been reported with regards to the involvement of ADCC by NK and/or NK T cells in M2emediated protection (35,49). Jegerlehner et al. proposed an
important role for ADCC by NK cells in acquiring antiM2e immunity (35). Meanwhile, other studies (49,50) argued for a different immune mechanism by M2e-mediated
protection rather than NK cell-mediated ADCC. Considering several differences in experimental protocols, it is difficult to reconcile contradictory findings on the role of NK
cells in the M2e-mediated protection in mice. Recently, it
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has been reported that human NK cell-mediated ADCC
against M2-expressing cells as well as pro-inflammatory
cytokine and chemokine secretion from NK cells were enhanced in the presence of human anti-M2e monoclonal antibody Ab1-10 (51). Thus, it is likely that NK cells may
contribute to M2e immune mediated protection via multiple mechanisms.

Roles of complement protein C3 in conferring cross
protection by M2e vaccines
Complement can also play an essential role in virus elimination (52-54). Beebe et al. reported that complement can
bind to influenza virus in the presence of virus-specific antibodies (55). Moreover, the classical complement pathway
can be activated by antigen-antibody immune complexes,
ultimately leading to CDC. However, the role of complement in M2e-mediated immune response is also controversial. Jegerlehner et al. demonstrated that the complement
component C3 is not critical for anti-M2e antibody-mediated protection by intraperitoneal passive transfer of M2eimmune sera (35). In contrast, Wang et al. suggested that
complement is required for reducing lung viral loads in infected mice using passive immunization of human anti-M2e monoclonal antibodies in C3−/− mice model (56).
This discrepancy might be due to the differences in experimental protocols. The IgG2a isotype antibody is known to
be involved in binding to FcRs more effectively than IgG1
isotype (44,57-59). Mice were immunized by M2-hepatitis
B core (M2-HBc) particles used in Jegerlehner’s experiments showed that endpoint titers of M2e-specific IgG1
isotype antibody were approximately 10-fold higher than
that of M2e-specific IgG2a isotype antibody (23). It is possible that a profile of specific IgG isotypes might play a
role in differential effects on the dependency of FcRs or
complement. Further studies are needed to better understand the possible roles of complement C3 in conferring
protection by using an appropriate vaccine that can elicit
a T helper type 1-biased antibody immune response.
Roles of M2e-specific T cell responses in conferring
M2e immunity by vaccination
Optimum protection against influenza A virus requires antibody production by B cells as well as cytotoxic cellular
and soluble cytokine mechanisms mediated by T cells (60).
Activated influenza-specific T cells have been shown to
be associated with protection against influenza in human

studies (61,62). Several studies have shown that M2e-specific T cells can mediate protection against influenza infection in vivo (16,19,30,48). Eliasson et al. have demon＋
＋
strated that an M2e-specific CD4 T cell but not CD8
T cell response was induced in BALB/c mice that were
intranasally immunized with protein fusion vaccine
(CTA1-M2e-DD of cholera toxin subunit A1 and a dimer
of the D-fragment of Staphylococcus aureus protein A) in
the presence of immune stimulatory complex ISCOMS ad＋
juvant (19). Anti-influenza CD8 cytotoxic T lymphocyte
activity is also known to contribute to recovery from influenza infection in mice (63). Other studies have demonstrated the presence of MHC class I or II restricted epitopes
in M2e in mice or human (64-66). Although it is not clear
why there is discrepancy in T cell responses among different studies, differences in immunization protocols such as
the platforms of vaccines and adjuvants, strains of animals,
routes of immunization and with or without adjuvants may
affect the differential outcomes of immune responses.
Specific T cell depletion approaches in vaccinated mice
are often used to determine the roles of T cells in conferring protection. In a previous study of M2-DNA and adenoviral vector vaccines (16), BALB/c mice that were immunized with M2-DNA prime and M2-recombinant adenovirus boost were treated with CD4, CD8, or CD4 plus
CD8 antibodies prior to viral challenge. M2-DNA/adenovirus immune mice with depletion of both CD4＋ and
＋
＋
＋
CD8 T cell but not either single CD4 or CD8 T cell
showed significant lower efficacy of survival protection indicating the roles of CD4＋ and CD8＋ T cells in conferring
M2 immunity (16). Using a similar approach, Kim et al.
＋
have reported differential effects on the roles of CD4 and
＋
CD8 T cells in mice that were immunized with split vaccine plus M2e5x VLP (30). Split-M2e5x VLP immune
＋
mice with depletion of CD4 T cells showed significant
more weight loss than the CD8＋ T cell depleted mice, in＋
dicating that CD4 T cells appeared to play a greater role
＋
than CD8 T cells in conferring cross protection (30). Of
course, severe weight loss was observed in Split-M2e5x
＋
VLP immune mice with depletion of both CD4 T and
＋
＋
CD8 T cells, providing further evidence that both CD4
＋
T and CD8 T cells play an important role conferring
cross protection via M2e-based vaccines. In line with these
−/−
mice inabove studies, M2e5x VLP immune FcR γ
duced higher frequency of M2e-specific IFN-γ-producing
＋
＋
CD4 and CD8 T cells as well as lower lung viral titers
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−/−

compared to those of naïve FcR γ mice post challenge
＋
(48). Therefore, it is likely that M2e-specific CD4 and
CD8＋ T cell immunity plays an important role during recovery from illness caused by influenza virus infection if
immunogenic M2e vaccines are used to induce T cell
immunity.

SUPPLEMENTED VACCINATIONS WITH A
REALISTIC GOAL OF CONFERRING
BROADER CROSS PROTECTION
Developing a truly cross protective single shot universal
vaccine might not be a realistic goal due to the extremely
high genetic and antigenic differences among influenza viruses as well as the relatively low immunogenicity and efficacy of conserved antigenic targets. To overcome the low
immunogenicity and efficacy of M2e, most animal studies
were carried out using M2e-conjugate vaccines in a range
of high doses (40 to 100 µg per mouse) and multiple immunizations in the presence of potent adjuvants inappropriate for human use.
A more realistic approach for inducing broader cross
protection would be to supplement current platforms of
strain-sepcific HA-based influenza vaccines with a highly
conserved antigenic target vaccines such as M2e. Song et
al. (2011) demonstrated that an inactivated influenza vaccine supplemented with M2 VLPs can significantly improve cross protective efficacy by preventing weight loss
and conferring protection against H1N1, H3N2, and H5N1
influenza viruses (29). In a recent study to further support
the concept of supplemented vaccination, co-immunization
with licensed split vaccine plus M2e5x VLP significantly
improved the efficacy of cross protection compared to that
of split vaccine alone (30). Also, immune sera from supplemented vaccination were shown to confer improved
cross protection in naïve mice (30). In real world, most
humans have a certain level of pre-existing immunity to
influenza either by vaccination or natural infection. To
mimic this heterogeneity with pre-existing immunity, mice
that were previously immunized with split vaccine were
subsequently immunized with M2e5x VLPs and evaluated
to assess the cross protective efficacy against heterosubtypic viruses (22). Subsequent supplemental immunization with M2e5x VLPs significantly enhanced the cross
protective efficacy of pre-existing HA immunity (22). To
further move forward this concept of supplementation with
218

a conserved M2e epitope vaccine to clinical trials, the efficacy of M2e5x VLP supplementation should be tested in
a more relevant ferret animal model.

CONCLUSION
Influenza viruses are continuously evolving, introducing
various mutations to the surface glycoproteins HA and
NA, or transferring new HA and/or NA genes from other
species stains to human influenza viruses. Current vaccination is based on immunity to HA, mainly aiming to induce vaccine strain-specific neutralizing antibodies. When
the prediction of a circulating strain in the next season is
well matched with a chosen vaccine strain, the efficacy is
sufficiently high. However, current strategy has a major
drawback of being unable to protect against a new strain
with an antigenically different HA.
The concept behind developing universal vaccines is to
utilize the highly conserved antigenic target such as M2e
and to make it immunogenic sufficient enough for inducing protective immunity. However, the protective immune
mechanisms of the immune responses induced by M2e
vaccination remain to be fully elucidated and further studies are needed for a better understanding. It will provide
highly informative insight into developing novel new vaccines if we better understand the immunological mechanisms of how universal vaccines work and what immune
components involve in the protection against different
strains of influenza A virus. Based on mechanistic understanding, it is expected that effective and safe M2e-specific
influenza vaccines will be developed for prevention of seasonal and pandemic influenza in near future.
A caveat is that most human vaccines were licensed by
proven criteria of inducing neutralizing antibodies. As reviewed above, protective immune mechanisms by which
M2e immunity works rely on the induction of cross protective non-neutralizing antibodies and T cell responses.
Due to the nature of M2 immune-mediated protection, developing standalone broadly cross protective universal influenza vaccines to completely replace the current annually
updating influenza vaccination program would be an ideal
goal. Instead, an achievable approach will be to develop
simple vaccination of supplementing strain-specific current
influenza vaccines with a highly conserved M2e antigenic
target in an effective platform such as VLPs.
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